The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

J. Renouf, Daniel; M. Loree, Jonathan; J. Knox, Jennifer; T. Topham, James; Kavan, Petr; J. Jonker, Derek; Welch, Stephen; Couture, Félix; Lemay, Frédéric; Tehfé, Mustapha; Harb, Mohammed; Aucoin, Nathalie; Ko, Yoo‐Joung; A. Tang, Patricia; Ramjeesingh, Ravi; M. Meyers, Brandon; Kim, Christina; Du, Pan; Jia, Shidong; F. Schaeffer, David; Gill, Sharlene; Tu, Dongsheng; J. O’Callaghan, Chris

doi:10.1038/s41467-022-32591-8

Public

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Published in Nature Communications • Aug 26, 2022

Authors:

Daniel J. Renouf

Jonathan M. Loree

Jennifer J. Knox

Abstract

Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair deficiency setting, while safety and efficacy of combining dual-checkpoint inhibitor immunotherapy with chemotherapy remains uncertain. Here, we p...

Subject

Gemcitabine

Durvalumab

Nab-paclitaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!